Summary:
- Verdiva Bio, a biotech startup, has raised a $41.1 million Series A funding round to develop its platform for designing and manufacturing novel biologics.
- The company's technology aims to accelerate the development of biologic drugs by combining computational design, high-throughput screening, and machine learning.
- Verdiva Bio plans to use the funding to expand its team, advance its pipeline of drug candidates, and further develop its proprietary platform for designing and engineering biologics.